A vs QGEN vs DHR Stock Comparison

Agilent Technologies, Qiagen and Danaher Prices as of Oct 23, 2026 Peers: Industry group
A Agilent Technologies, Inc.
$173.05 +4.7% 1M +17.4% 1Y
Market cap
$49.59B
P/E
34.4x
Revenue (TTM)
$7.37B
Div. yield
0.01%
Life Sciences Tools Healthcare
6 wins
QGEN Qiagen N.V.
$50.38 +15.3% 1M -3.0% 1Y
Market cap
$10.94B
P/E
26.7x
Revenue (TTM)
$2.10B
Div. yield
–
Life Sciences Tools Healthcare
3 wins
DHR Danaher Corp /De/
$230.44 +3.9% 1M +3.5% 1Y
Market cap
$164.19B
P/E
41.0x
Revenue (TTM)
$25.11B
Div. yield
–
Life Sciences Tools Healthcare
2 wins

Head to Head

11 decided of 12

Agilent Technologies leads on 6 of the 12 questions below (Agilent Technologies 6, Qiagen 3, Danaher 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionAQGENDHRLeader
Larger companyMarket capitalisation $49.59B $10.94B $164.19B DHR
Cheaper on earningsLower P/E, profitable companies only 34.4x 26.7x 41.0x QGEN
Cheaper on forward earningsLower price / next fiscal year consensus EPS 26.5x 21.4x 25.5x QGEN
Faster revenue growthRevenue growth, trailing twelve months +8.6% +3.0% +4.6% A
More profitableNet margin, trailing twelve months 19.5% 19.5% 15.9% A
Better return on capitalReturn on invested capital 13.1% 7.9% 5.7% A
Less leveragedLower net debt / EBITDA 1.1x 1.3x 2.9x A
Higher dividend yieldTrailing dividend yield 0.01% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +17.4% -3.0% +3.5% A
Better 5-year returnAnnualised price return, 5 years +1.8%/yr -3.5%/yr -6.0%/yr A
Less volatileAnnualised volatility, 1 year 32.3% 35.8% 30.6% DHR
Higher overall scoreMean of the five percentile scores vs peers 62/100 71/100 60/100 QGEN

Percentile Scorecard

AQGENDHR

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisAQGENDHR
Valuation 57 #98 of 228 76 #56 of 228 67 #75 of 228
Growth 36 #143 of 222 29 #158 of 222 20 #178 of 222
Profitability 91 #20 of 210 93 #16 of 210 88 #27 of 210
Financial Health 55 #108 of 241 63 #90 of 241 46 #131 of 241
Shareholder Returns 69 #43 of 138 93 #10 of 138 77 #32 of 138
Overall 62 71 60
  • A ranked among 248 companies in Medical Devices and Diagnostics
  • QGEN ranked among 248 companies in Medical Devices and Diagnostics
  • DHR ranked among 248 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodAQGENDHRSPY
1 month +4.7%+15.3%+3.9% -1.0%
3 months +24.9%+21.7%+20.3% +2.9%
6 months +49.8%+31.2%+30.0% +6.4%
Year to date +27.2%+6.4%+0.7% +11.4%
1 year +17.4%-3.0%+3.5% +13.1%
3 years +63.8%+20.7%+17.1% +79.4%
3 years, per year +17.9%+6.5%+5.4% +21.5%
5 years +9.5%-16.4%-26.5% +67.7%
5 years, per year +1.8%-3.5%-6.0% +10.9%
10 years +279.7%+68.5%+187.4% +255.2%
10 years, per year +14.3%+5.4%+11.1% +13.5%

Risk

MeasureAQGENDHRSPY
Volatility, 1Y 32.3%35.8%30.6% 12.7%
Downside volatility, 1Y 27.5%30.5%31.7% 12.7%
Beta vs S&P 500, 1Y 0.860.450.44 1.00
Return / volatility, 1Y 0.54-0.080.11 1.03
Max drawdown, 5Y -39.6%-48.2%-50.8% -25.4%
From 52-week high -2.6%-9.5%-4.8% -2.5%
52-week high $177.72$55.66$242.05 $779.14
52-week low $110.24$32.63$161.91 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleAQGENDHR
P/E now vs peer median 33.9xmedian 30.7x 26.7xmedian 30.7x 40.6xmedian 30.7x
P/S now vs peer median 6.6xmedian 3.0x 5.2xmedian 3.0x 6.5xmedian 3.0x
EV/EBITDA now vs peer median 26.7xmedian 17.7x 18.1xmedian 17.7x 24.0xmedian 17.7x
P/FCF now vs peer median 38.5xmedian 23.7x 11.0xmedian 23.7x 29.6xmedian 23.7x
P/B now vs peer median 6.6xmedian 2.4x 3.3xmedian 2.4x 3.1xmedian 2.4x
PEG now vs peer median 3.45median 0.96 3.62median 0.96 -3.24median 0.96

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsAQGENDHR
Revenue $7.37B $2.10B $25.11B
Gross profit $3.97B $1.31B $14.69B
Operating income $1.64B $445.43M $5.13B
Net income $1.44B $409.32M $4.00B
Free cash flow $1.27B $991.33M $5.47B
R&D $485.00M $194.67M $1.62B
EPS (diluted) $5.09 $1.87 $5.66
Cash & equivalents $1.76B $768.50M $4.35B
Total debt $3.95B $6.86B $26.56B
Shares (diluted) 283.00M 218.88M 707.60M
Enterprise value $42.48B $6.71B $148.00B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricAQGENDHR
P/E 33.9x 26.7x 40.6x
P/FCF 38.5x 11.0x 29.6x
P/Operating cash flow 30.3x 16.7x 24.4x
P/S 6.6x 5.2x 6.5x
P/B 6.6x 3.3x 3.1x
P/Tangible book 7.6x 3.6x 5.2x
EV/EBITDA 26.7x 18.1x 24.0x
EV/EBIT 31.1x 26.4x 35.9x
EV/Revenue 6.9x 5.6x 7.3x
EV/FCF 40.2x 11.9x 33.7x
EV/Operating cash flow 31.7x 18.0x 27.8x
PEG (3Y EPS CAGR) 3.45 3.62 -3.24

Growth

14 metrics
MetricAQGENDHR
Revenue growth (1Y) 8.6% 3.0% 4.6%
Revenue CAGR (3Y) 1.8% 2.0% -0.5%
Gross profit growth (1Y) 11.2% 1.7% 2.6%
Gross profit CAGR (3Y) 3.7% 1.3% -0.9%
Operating income growth (1Y) 13.5% -4.9% 16.1%
Operating income CAGR (3Y) 5.1% 3.3% -7.1%
Net income growth (1Y) 18.0% 143.9% 17.3%
Net income CAGR (3Y) 8.3% 6.7% -14.3%
EPS growth (1Y) 18.9% 12.5% 19.2%
EPS CAGR (3Y) 9.8% 7.4% -12.5%
Operating cash flow growth (1Y) 7.6% -3.0% 7.6%
Operating cash flow CAGR (3Y) -1.9% 8.0% -7.6%
Free cash flow growth (1Y) 16.5% 2.3% 12.4%
Free cash flow CAGR (3Y) -3.7% 10.5% -9.0%

Profitability

14 metrics
MetricAQGENDHR
Gross margin 53.8% 62.2% 58.5%
EBITDA margin 25.9% 31.0% 30.5%
Operating margin 22.2% 21.2% 20.4%
Pretax margin 22.5% 22.0% 19.0%
Net margin 19.5% 19.5% 15.9%
FCF margin 17.2% 47.2% 21.8%
Operating cash flow margin 21.8% 31.2% 26.4%
Return on equity 19.9% 12.2% 7.6%
Return on assets 10.7% 7.0% 4.5%
Return on invested capital 13.1% 7.9% 5.7%
Return on capital employed 14.6% 8.5% 6.4%
Asset turnover 0.5x 0.4x 0.3x
Cash conversion (OCF / net income) 1.1x 1.6x 1.7x
Stock comp / revenue 1.8% 2.1% 1.2%

Financial Health

11 metrics
MetricAQGENDHR
Debt / assets 28.3% 27.9% 28.8%
Debt / equity 0.5x 0.5x 0.5x
Net debt / EBITDA 1.1x 1.3x 2.9x
Debt / FCF 3.1x 1.7x 4.9x
Liabilities / assets 47.3% 43.0% 43.1%
Equity / assets 52.7% 57.0% 56.9%
Interest coverage 15.5x 11.3x 17.6x
Current ratio 2.1x 2.8x 1.7x
Quick ratio 1.4x 2.0x 1.0x
Cash ratio 0.8x 1.4x 0.5x
Altman Z-score 5.75 4.08 3.70

Shareholder Returns

7 metrics
MetricAQGENDHR
Dividend yield 0.6% 5.2% 0.7%
Net buyback yield 0.6% 0.6% 1.8%
Shareholder yield 1.2% 5.8% 2.5%
Payout ratio (earnings) 19.9% – –
Payout ratio (FCF) 22.6% – –
Dividend growth (1Y) 2.1% – –
Dividend CAGR (3Y) 3.1% – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusAQGENDHR
Forward P/E 26.5xFY2026 21.4xFY2026 25.5xFY2026
EPS, next fiscal year $6.54FY2026 $2.35FY2026 $9.03FY2026
EPS growth, next FY +17.0%FY2026 -1.3%FY2026 +15.8%FY2026
EPS growth, the year after +0.6% +17.9% +8.9%
Revenue, next fiscal year $7.87BFY2026 $2.25BFY2026 $27.12BFY2026
Revenue growth, next FY +15.3%FY2026 +7.8%FY2026 +10.4%FY2026
Revenue growth, the year after -5.6% -2.8% -1.6%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersAQGENDHR
Held by institutions 92.6% 67.3% 81.9%
Institutions holding 1,122 337 2,115
Change in shares held, QoQ +3.2% +16.5% +1.1%
Institutions buying 599 215 837
Institutions selling 350 86 1,015
Buyers to sellers 1.71 2.50 0.82

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

AQGENDHR
A 1.00 0.38 0.60
QGEN 0.38 1.00 0.38
DHR 0.60 0.38 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, A, QGEN and DHR?

Danaher (DHR) is the largest by market capitalisation: Agilent Technologies (A) $49.59B, Qiagen (QGEN) $10.94B, Danaher (DHR) $164.19B.

Which stock is cheaper, A, QGEN and DHR?

Qiagen (QGEN) trades on the lowest price-to-earnings ratio (Agilent Technologies (A) 34.4x, Qiagen (QGEN) 26.7x, Danaher (DHR) 41.0x). On next year's consensus earnings, Qiagen (QGEN) is cheapest (Agilent Technologies (A) 26.5x, Qiagen (QGEN) 21.4x, Danaher (DHR) 25.5x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Agilent Technologies (A) grew revenue fastest over the trailing twelve months: Agilent Technologies (A) +8.6%, Qiagen (QGEN) +3.0%, Danaher (DHR) +4.6%.

Which company is more profitable?

Agilent Technologies (A) has the highest net margin (Agilent Technologies (A) 19.5%, Qiagen (QGEN) 19.5%, Danaher (DHR) 15.9%). On return on invested capital, Agilent Technologies (A) leads (Agilent Technologies (A) 13.1%, Qiagen (QGEN) 7.9%, Danaher (DHR) 5.7%).

Which stock has performed better?

Over the past year Agilent Technologies (A) returned the most: Agilent Technologies (A) +17.4%, Qiagen (QGEN) -3.0%, Danaher (DHR) +3.5%. Over five years, Agilent Technologies (A) compounded fastest (Agilent Technologies (A) +1.8%/yr, Qiagen (QGEN) -3.5%/yr, Danaher (DHR) -6.0%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Agilent Technologies (A) 0.01%, Qiagen (QGEN) 0.00%, Danaher (DHR) 0.00%. Qiagen (QGEN) and Danaher (DHR) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Danaher (DHR) has been the steadiest (Agilent Technologies (A) 32.3%, Qiagen (QGEN) 35.8%, Danaher (DHR) 30.6%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, A, QGEN and DHR?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Agilent Technologies (A) leads on 6. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.